Clinical Trial

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The DCMG regimen includes decitabine or azacitidine (hypomethylating agents), mitoxantrone liposome, cytarabine, and granulocyte colony-stimulating factor (G-CSF), comprising four medications. This project initiates a prospective and exploratory clinical study on the DCMG chemotherapy regimen for the treatment of relapsed/refractory AML (Acute Myeloid Leukemia). The study aims to evaluate the efficacy and safety of the DCMG combination chemotherapy regimen in treating relapsed/refractory AML.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-15.
Trial Details
NCT Number NCT06741722
Lead Sponsor Beijing 302 Hospital
Conditions AML, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Enrollment 20 participants
Start Date 2024-10-31
Primary Completion 2026-10-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-27